This group will discuss topics related to the actual implementation and regulatory implications of the continuous manufacturing of Active Pharmaceutical Ingredients (APIs) and Oral Solid Dose products.

To enrich our discussions and provide valuable insights, please include concrete examples and research links in your posts. This not only strengthens your thoughts but also benefits the entire community by offering reliable resources and evidence.